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Improved Arousal and Motor Function Using Zolpidem in a Patient
With Space-Occupying Intracranial Lesions: A Case Report
Martin Nicholas Bomalaski, MD, Sean Robinson Smith, MDAbstractPatients with disorders of consciousness (DOC) have profound functional limitations with few treatment options for improving
arousal and quality of life. Zolpidem is a nonbenzodiazepine hypnotic used to treat insomnia that has also been observed to
paradoxically improve arousal in those with DOC, such as the vegetative or minimally conscious states. Little information exists on
its use in patients with DOC who have intracranial space-occupying lesions. We present a case of a 24-year-old man in a minimally
conscious state due to central nervous system lymphoma who was observed to have increased arousal and improved motor
function after the administration of zolpidem.
Level of Evidence: VIntroduction
Zolpidem is a nonbenzodiazepine hypnotic that is
approved by the Food and Drug Administration for the
short-term treatment of insomnia, with activity as a
selective agonist of the omega-1 GABAa receptor sub-
type [1]. In 2000, Clauss et al [2] published a report of a
young man who had been in a vegetative state (VS) for
3 years after a motor vehicle accident who regained
consciousness 15 minutes after receiving 10 mg of zol-
pidem. He was able to respond appropriately to envi-
ronmental stimuli and communicate verbally with his
family. The effects lasted approximately 3 hours before
he returned to his VS. The effects were, however,
reproducible with repeated administrations, dramati-
cally improving the patient’s function and quality of life
[2]. Those with disorders of consciousness (DOC) have
profound functional limitations and generally are unable
to participate in their own self-care, creating a high
caregiver and health system burden. Treatment options
to improve cognitive awareness and overall function
remain limited to a small number of agents, including
amantadine, apomorphine, and levodopa, with limited
evidence for their efficacy [3].
To date, zolpidem’s paradoxical effects in this pop-
ulation primarily have been reported in patients with
brain injury secondary to trauma, nontraumatic anoxia,1934-1482/$ - see front matter ª 2017 by the American Academy of Physi
http://dx.doi.org/10.1016/j.pmrj.2016.12.011or stroke [4]. There is little information on its use in
patients with DOC who have intracranial space-
occupying lesions. We present a case of a young man
with central nervous system (CNS) lymphoma in a
minimally conscious state (MCS) who was seen to have
increased arousal and improved motor function after
the administration of zolpidem.
Case Presentation
A previously healthy 24-year-old man presented to his
local hospital with several weeks of worsening frontal
headache, impaired coordination, and behavioral
changes. Magnetic resonance imaging of his brain
revealed a left frontal lobe lesion involving the basal
ganglia with periventricular enhancement, cross-over at
the corpus callosum, rightward midline shift, and sat-
ellite lesions in the left frontal lobe and cerebellum.
Biopsy results were consistent with primary CNS B-cell
lymphoma. Further workup revealed him to be positive
for HIV, and he was started on antiretroviral therapy.
After 1 week, he had multiple episodes of generalized
seizure activity and was intubated for airway protec-
tion. At that time, he was reported to have right-sided
hemiparesis and decreased arousal. On day 10, he
became febrile and began decerebrate posturing and
subsequently was transferred to our tertiary carecal Medicine and Rehabilitation
Table 1
Assessment scores for zolpidem trials days 1 and 2
Assessment
Day 1 Day 2
0 45 min 1 1 h 2 h 4 h
GCS
Motor 4 6 4 4 6 6
Verbal 1 1 4 1 4 2
Eyes 4 4 1 1 1 1
Total 9 11 9 6 11 10
DRS
Eyes 0 0 0 2 0 2
Communication 4 4 4 4 4 4
Motor 2 0 2 2 0 0
Feeding 3 2 3 3 2 2
Toileting 3 3 3 3 3 3
Grooming 3 3 3 3 3 3
Function 5 5 5 5 5 5
Employability 3 3 3 3 3 5
Total 23 20 23 25 20 24
CRS-R
Auditory 4 1 4
Visual 5 1 5
Motor 2 2 5
Oromotor 1 1 2
Communication 0 0 1
Arousal 1 1 2
Total 13 6 19
GCS ¼ Glasgow Coma Scale; DRS ¼ Disability Rating Scale; CRS-R ¼
Coma Recovery Scale- Revised.
832 Zolpidem in a Patient With Space-Occupying Lesionshospital for further management. Ultimately, a trache-
ostomy was performed because of hypoxemic respira-
tory failure related to pneumonia.
Once weaned off of sedation and mechanical ventila-
tion, he was found to be in an MCS, inconsistently
following simple commands on his left, and answering
yes/no questions using nonverbal gestures. Right-sided
hemiparesis remained, and both upper and lower ex-
tremity spasticity worsened (Modified Ashworth Scale
score of 3), for which he was started on baclofen 10 mg 3
times a day. He received methotrexate and rituximab
chemotherapy soon after admission for CNS lymphoma,
but further treatments were held due to his medical
instability. He also received radiation therapy that ended
on hospital day 74. He also was started on amantadine
100 mg twice a day; however, there was no significant
improvement in his level of cognitive awareness or
participation in self-care, which remained total assist
across all domains of the Functional Independence Mea-
sure. Repeat magnetic resonance imaging of the brain
showed progression of his CNS lymphomawith increase in
size of the frontal lobe and cerebellar lesions. Because of
his poor functional status and disease progression, addi-
tional oncologic treatments were held.
A rehabilitation consult was requested to provide
spasticity management and recommendations for
mobility and decreased arousal. As part of the consult,
on hospital day 126 a trial of zolpidem was suggested to
improve arousal, given that the patient remained in an
MCS, inconsistently following simple commands, and
answering yes/no questions using nonvocal gestures.
The trial was performed in the morning using 10 mg
zolpidem administered via feeding tube. The Disability
Rating Scale (DRS), an outcome measure that was
developed to track functional recovery in patients with
traumatic brain injury (lower score represents greater
function) [5], and the Glasgow Coma Scale (GCS), which
assesses level of consciousness in brain injured patients
(greater score represents greater function) [6], were
administered premedication and 45 minutes after
administration. The DRS was selected to track changes in
global function, whereas the GCS would focus on level of
consciousness. Forty-five minutes was chosen because
previous reports have shown that zolpidem often takes
effect on patients with DOC around 30-60 minutes [4].
At 45 minutes postadministration of zolpidem, the
patient initially appeared more somnolent, but quickly
awoke with tactile stimulation, and was noticeably more
interactive than before receiving the medication. He
displayed functional object use, such as demonstrating
how to drink from a cup and use a pen. There was
improvement in both GCS and DRS, primarily in the do-
mains of motor function (Table 1). He also could follow
simple commands, such as waving to or giving thumbs up.
Verbal scores were not able to be assessed, because an
uncapped tracheostomy impaired his ability to speak or
otherwise volitionally generate audible sounds.Because of the improvements seen in the first trial, a
more extensive second trial was conducted 2 days later,
this time also including the Coma Recovery Scale-
Revised (greater score represents greater function), in
addition to the GCS and DRS. The Coma Recovery Scale-
Revised is a standardized functional scale validated in
the DOC population [7]. Again, 10 mg was administered
in the morning, and assessments were made before and
at 1, 2, and 4 hours after administration. GCS and DRS
scores before administration of zolpidem (“baseline”)
were unchanged from those of the first trial. One hour
after administration, he had a decline in function,
appearing somnolent, not opening his eyes to painful
stimuli, and not following commands. At 2 hours there
was significant improvement from baseline in regards to
arousal, communication, and motor function. He could
again demonstrate functional object use with a cup and
ball. He could consistently answer simple yes/no ques-
tions using thumbs up/down, respectively. At 4 hours,
he had returned to near baseline. This trend was
consistent across all outcomes (Table 1). The patient
was discharged to a skilled nursing facility the following
night, and passed away a few weeks later before any
follow-up evaluations.Discussion
To date, there is little known about the effects of
zolpidem on arousal in patients with DOC who have
833M.N. Bomalaski, S.R. Smith / PM R 9 (2017) 831-833intracranial space-occupying lesions. To our knowledge,
this is one of the first reports of its off-label use in this
population. In 2014, Du et al [8] performed a study in
which they obtained single-photon positron emission
tomography and cerebral state monitoring before and 1
hour after administering zolpidem to 165 subjects in a
VS. Of these subjects, 40 had brain injury due to a
space-occupying mass, typically either a tumor or he-
matoma. As a group they showed significant improve-
ment across all measures. Average age among this group
was 38.5 years and duration since time of injury was 62
days. Additional information, such as cause and location
of the space-occupying lesion, or percentage of subjects
who responded to zolpidem were not provided.
The omega-1 GABAa receptors that zolpidem binds
selectively to are found in large quantities in the output
structures of the basal ganglia, namely the globus
pallidus interna and substantia nigra pars reticularis.
Zolpidem’s paradoxical effects in increasing arousal in
patients with DOC may lie its ability to inhibit these
inhibitory structures, thus helping to restore a norma-
tive balance between these pathways [9].
In regards to adverse effects, this was limited to
sedation, which was seen at the 1-hour assessment
during trial 2. Despite zolpidem’s sedative properties,
its occurrence in this population is less common than
one might expect, with only 2 of 83 subjects showing
signs of sedation in 2014 study by Whyte et al [4]. Zol-
pidem has been shown to reach peak plasma levels
around 0.75-2.6 hours after administration, with a half-
life of around 2.4 hours [1]. Our observation of improved
function at 45 minutes after administration during the
first trial and increased sedation at 1 hour followed by
improvement at 2 hours on the second trial was most
likely due to the natural fluctuations in level of con-
sciousness seen in patients with DOC. There are some
data to suggest a bimodal response; however, no con-
clusions can be made based on these limited data.
Whyte et al observed a similar biphasic response in a
zolpidem responder who had received 10 mg. They
initially hypothesized that there may be an optimal
therapeutic window; however, subsequent trials using 5
mg did not support this hypothesis, and the changes
were attributed to behavioral variability, which is
common among patients with DOC [10]. Although wecannot rule out the possibility that the changes we
observed in response to zolpidem were due entirely to
natural fluctuations, this seems less likely, considering
similar changes were seen in 2 separate trials. The
timing of changes we observed also were consistent with
previous reports [4].
As a single case report, it is uncertain how predictive
our findings are for a similar response in other patients
with DOC who have space-occupying lesions. Future in-
vestigations are required to determine the safety and
efficacy of zolpidem at various dosages in treating those
with DOC in general and with space-occupying lesions in
particular. Correlation of clinical response with func-
tional neuroimaging may also aid in predicting who will
respond to this intervention. We do, however, recognize
the logistical challenges in conducting large trials in
such an uncommon disorder with a high level of het-
erogeneity in regards to underlying brain injury.References
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